LATEST & GREATEST

RESEACH HIGHLIGHTS

관리자 2021-02-02 Views 1,108

Type I IFN Exacerbates Disease in Tuberculosis Susceptible Mice by Inducing Neutrophil-mediated Lung Inflammation and NETosis



AUTHORS

Lúcia Moreira-Teixeira, Philippa J. Stimpson, Evangelos Stavropoulos, Sabelo Hadebe, Probir Chakravarty, Marianna Ioannou, Iker Valle Aramburu, Eleanor Herbert, Simon L. Priestnall, Alejandro Suarez-Bonnet, Jeremy Sousa, Kaori L. Fonseca, Qian Wang, Sergo Vashakidze, Paula Rodríguez-Martínez, Cristina Vilaplana, Margarida Saraiva, Venizelos Papayannopoulos & Anne O’Garra

 

SUMMARY

Tuberculosis (TB) is a leading cause of mortality due to infectious disease, but the factors determining disease progression are unclear. Transcriptional signatures associated with type I IFN signaling and neutrophilic inflammation were shown to correlate with disease severity in mouse models of TB. Here we show that similar transcriptional signatures correlate with increased bacterial loads and exacerbate pathology during Mycobacterium tuberculosis infection upon GM-CSF blockade. Loss of GM-CSF signaling or genetic susceptibility to TB (C3HeB/FeJ mice) result in type I IFN-induced neutrophil extracellular trap (NET) formation that promotes bacterial growth and promotes disease severity. Consistently, NETs are present in necrotic lung lesions of TB patients responding poorly to antibiotic therapy, supporting the role of NETs in a late stage of TB pathogenesis. Our findings reveal an important cytokine-based innate immune effector network with a central role in determining the outcome of Mtuberculosis infection.

 

REFERENCES

Lúcia Moreira-Teixeira et al. Type I IFN exacerbates disease in tuberculosis-susceptible mice by inducing neutrophil-mediated lung inflammation and NETosis. Nature Communications volume 11, Article number: 5566 (2020). https://doi.org/10.1038/s41467-020-19412-6

 

PRODUCT HIGHLIGHTS

The following Bio X Cell in vivo grade monoclonal antibodies were featured in the publication:

Tags: Research Highlights


Prev
RESEACH HIGHLIGHTS
Next
No next article.